Elucidation of a potent pro-resolving mediator of inflammation resolution via human neutrophil-vascular endothelial cell interactions.
Summary
The authors identify a previously unknown DHA-derived specialized pro-resolving mediator, 4,13-diHDHA (4S,13R-diHDHA), generated via endothelial COX-2 and neutrophil 5-LOX crosstalk. Structural elucidation and recombinant enzyme validation support its biosynthesis, and the lipid exerts nanomolar pro-resolving actions across multiple human and mouse systems.
Key Findings
- Discovery and structural elucidation of a novel DHA-derived mediator, 4,13-diHDHA (4S,13R), produced via endothelial COX-2 and neutrophil 5-LOX crosstalk.
- Nanomolar pro-resolving actions include limiting neutrophil infiltration, reducing neutrophil–endothelial adhesion, protecting endothelial cells from senescence, and stimulating macrophage efferocytosis.
- Metabololipidomics and recombinant enzyme studies validate biosynthetic pathways during leukocyte–vascular interactions.
Clinical Implications
Supports development of resolution-based therapeutics (e.g., SPM analogs) that could reduce inflammatory injury in perioperative, critical care, or cardiovascular settings.
Why It Matters
Defines a new pro-resolving lipid pathway at the leukocyte–endothelial interface with multi-system validation, offering mechanistic and therapeutic leads for controlling excessive inflammation.
Limitations
- Preclinical validation; clinical efficacy and safety in humans are unknown.
- Quantitative pharmacokinetics and stability in vivo require further characterization.
Future Directions
Optimize stable analogs and delivery, delineate receptor targets, and test efficacy in disease models relevant to perioperative or critical care inflammation.
Study Information
- Study Type
- Basic/Mechanistic research
- Research Domain
- Pathophysiology
- Evidence Level
- V - Preclinical biochemical and in vivo studies establishing a novel pathway
- Study Design
- OTHER